Clinical Research Directory

Inclusion Criteria: 1. Written informed consent 2. Age ≥ 18 years 3. Histologically proven DLBCL, including transformed follicular or marginal zone lymphoma 4. Measurable disease on cross-sectional imaging that is at least 1.5cm in the longest diameter and measurable in two perpendicular dimensions 5. Relapsed/refractory after 2 or more standard immuno-chemotherapies 6. Approved to receive Tisagenlecleucel as per the licenced indication 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 8. Disease accessible for repeat biopsies (Selected patients only) 9. Disease amenable to radiotherapy as assessed by the treating clinical oncologist 10. Willing and able to comply with the requirements of the protocol, including contraceptive advice as per the protocol Exclusion Criteria: 1. Prior radiotherapy at location/dose that would interfere with application of radiotherapy or outcome measures in this trial 2. Women who are pregnant or breast feeding 3. Previous therapy with any genetically modified autologous or allogeneic T-cell immunotherapy, unless treated with doses of genetically modified autologous or allogeneic T-cell immunotherapy within an abandoned dosing cohort in a first in human dose-escalation phase I clinical trial